CF
VIVO

Centaurus Financial’s Meridian Bioscience Inc VIVO Stock Holding History

Centaurus Financial’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-600
Closed -$10K – 2201
2018
Q2 		$10K Buy
+600
New +$8.95K ﹤0.01% 1567

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Centaurus Financial's VIVO Position: Q3 2018 in Review

Centaurus Financial sold out of Meridian Bioscience Inc (VIVO) in Q3 2018, closing a stake of 600 shares — an estimated $10K sold.

Centaurus Financial first reported a position in VIVO in Q2 2018 and held it in 1 quarter. The position peaked at $10K in Q2 2018. 177 funds tracked by Wall St. Rank hold VIVO as of Q3 2018.

  • Centaurus Financial reported no remaining Meridian Bioscience Inc position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 600 Meridian Bioscience Inc shares in Q3 2018, an estimated $10K.
  • Centaurus Financial first reported a position in Meridian Bioscience Inc in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Meridian Bioscience Inc position peaked at $10K in Q2 2018.
  • 177 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.